WallStreetZenWallStreetZen

NASDAQ: RPHM
Reneo Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for RPHM

Based on 3 analysts offering 12 month price targets for Reneo Pharmaceuticals Inc.
Min Forecast
$1.00-39.39%
Avg Forecast
$1.43-13.15%
Max Forecast
$1.80+9.09%

Should I buy or sell RPHM stock?

Based on 3 analysts offering ratings for Reneo Pharmaceuticals Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
3 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RPHM stock forecasts and price targets.

RPHM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-15
lockedlocked$00.00+00.00%2023-12-15
lockedlocked$00.00+00.00%2023-12-15

1 of 1

Forecast return on equity

Is RPHM forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.5%

Forecast return on assets

Is RPHM forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RPHM revenue forecast

What is RPHM's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$39.4M
Avg 2 year Forecast
$23.9M
Avg 3 year Forecast
$186.2M

RPHM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RPHM$1.65$1.43-13.15%Hold
ENTX$1.54$10.00+549.35%Buy
CLNN$0.43$6.00+1,311.76%Strong Buy
APLM$0.61$17.00+2,709.92%Buy
DARE$0.55$6.00+992.90%Buy

Reneo Pharmaceuticals Stock Forecast FAQ

Is Reneo Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: RPHM) stock is to Hold RPHM stock.

Out of 3 analysts, 0 (0%) are recommending RPHM as a Strong Buy, 0 (0%) are recommending RPHM as a Buy, 3 (100%) are recommending RPHM as a Hold, 0 (0%) are recommending RPHM as a Sell, and 0 (0%) are recommending RPHM as a Strong Sell.

If you're new to stock investing, here's how to buy Reneo Pharmaceuticals stock.

What is RPHM's revenue growth forecast for 2024-2026?

(NASDAQ: RPHM) Reneo Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Reneo Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RPHM's revenue for 2024 to be $1,312,484,408, with the lowest RPHM revenue forecast at $1,312,484,408, and the highest RPHM revenue forecast at $1,312,484,408. On average, 1 Wall Street analysts forecast RPHM's revenue for 2025 to be $797,151,063, with the lowest RPHM revenue forecast at $797,151,063, and the highest RPHM revenue forecast at $797,151,063.

In 2026, RPHM is forecast to generate $6,203,154,416 in revenue, with the lowest revenue forecast at $5,892,188,885 and the highest revenue forecast at $6,514,119,948.

What is RPHM's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RPHM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RPHM's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RPHM price target, the average RPHM price target is $1.43, with the highest RPHM stock price forecast at $1.80 and the lowest RPHM stock price forecast at $1.00.

On average, Wall Street analysts predict that Reneo Pharmaceuticals's share price could fall to $1.43 by Dec 15, 2024. The average Reneo Pharmaceuticals stock price prediction forecasts a potential downside of 13.15% from the current RPHM share price of $1.65.

What is RPHM's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RPHM) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.